Literature DB >> 18652995

Herpes simplex virus and HIV-1: deciphering viral synergy.

Philippe Van de Perre1, Michel Segondy, Vincent Foulongne, Abdoulaye Ouedraogo, Issouf Konate, Jean-Marie Huraux, Philippe Mayaud, Nicolas Nagot.   

Abstract

Recent proof-of-concept randomised controlled trials have shown a causal relation between herpes simplex virus (HSV) type 2 infection and HIV-1 replication in co-infected individuals. We explore the mechanisms that may operate to enhance reciprocal viral replication. Direct interactions could involve HIV-1-related immune deficiency, disruption of mucosal barrier by HSV infection/reactivation, HSV-induced mucosal cell recruitment, transactivation of HIV-1 replication by HSV proteins, and immune modulation by HSV decoys. Indirect interactions might coexist through disturbances of the vaginal flora during HSV shedding and systemic immune activation. In co-infected individuals, suppressive HSV treatment reduces HIV-1 genital and systemic excretion. This finding is a likely result of efficacious prevention of HSV2 reactivations, and perhaps of other herpesviruses. Strategies to control HSV2 and other herpesviruses deserve urgent attention and should become part of the HIV-1 prevention and care package.

Entities:  

Mesh:

Year:  2008        PMID: 18652995     DOI: 10.1016/S1473-3099(08)70181-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  85 in total

1.  Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation.

Authors:  Catia T Perciani; Bashir Farah; Rupert Kaul; Mario A Ostrowski; Salaheddin M Mahmud; Omu Anzala; Walter Jaoko; Kelly S MacDonald
Journal:  J Clin Invest       Date:  2019-01-22       Impact factor: 14.808

Review 2.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

3.  Herpes diagnostic tests and their use.

Authors:  Nicholas J Van Wagoner; Edward W Hook
Journal:  Curr Infect Dis Rep       Date:  2012-04       Impact factor: 3.725

4.  Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.

Authors:  Barb Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

5.  Unfortunate synergy between HIV and genital herpes.

Authors: 
Journal:  Can Fam Physician       Date:  2016-02       Impact factor: 3.275

6.  Genetic Diversity within Alphaherpesviruses: Characterization of a Novel Variant of Herpes Simplex Virus 2.

Authors:  Sonia Burrel; Nathalie Désiré; Julien Marlet; Laurent Dacheux; Sophie Seang; Eric Caumes; Hervé Bourhy; Henri Agut; David Boutolleau
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

7.  Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.

Authors:  Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

8.  SEROPREVALENCE AND RISK FACTORS OF HERPES SIMPLEX VIRUS TYPE 2 AMONGST PATIENTS' ATTENDING RETROVIRAL CLINIC IN FEDERAL MEDICAL CENTER ABEOKUTA, SOUTH-WEST NIGERIA.

Authors:  V U Nwadike; P Osinupebi; O Y Ojo; G B Imhonopi; O A Oyesola; C J Elikwu; W O Oladosu
Journal:  Ann Ib Postgrad Med       Date:  2020-06

Review 9.  Coinfecting viruses as determinants of HIV disease.

Authors:  Andrea Lisco; Christophe Vanpouille; Leonid Margolis
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

10.  A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.

Authors:  Christophe Vanpouille; Andrea Lisco; Marco Derudas; Elisa Saba; Jean-Charles Grivel; Beda Brichacek; Francesca Scrimieri; Raymond Schinazi; Dominique Schols; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.